Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23504916 | 0.95 | FOLH1 (0.50) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL30947360 | 0.95 | FOLH1 (0.50) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL563754 | 0.95 | FOLH1 (0.50) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL14079858 | 0.95 | FOLH1 (0.50) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL563755 | 0.95 | FOLH1 (0.50) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL22147959 | 0.92 | FOLH1 (0.40) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL22878289 | 0.91 | FOLH1 (0.47) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL17997383 | 0.91 | FOLH1 (0.47) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL30485724 | 0.90 | FOLH1 (0.44) | FOLH1TDP1CPB2ITGB3ITGA2B | |
| SCHEMBL14680455 | 0.90 | FOLH1 (0.43) | FOLH1TDP1CPB2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20190314515-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885TDP1 2364/4885CPB2 297/4885 |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885TDP1 2364/4885CPB2 297/4885 |
| US-20190314515-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885TDP1 2364/4885CPB2 297/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | FOLH1 1982/4885TDP1 495/4885CPB2 1167/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885TDP1 2364/4885CPB2 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.